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ABSTRACT 
Background: To improve the therapeutic ratio of radiation therapy, an increased knowledge 
of how dose distributions affect normal tissue outcomes is critically needed; however normal 
tissue outcomes in terms of self-reported atomized symptoms among gynecological cancer 
survivors are rare in the literature. 
Aims: To investigate the prevalence of self-reported symptoms and their impact on daily life 
among long-term gynecological cancer survivors previously treated with pelvic radiation 
therapy. In addition, we wanted to study how the dose-volume distribution of ionizing 
radiation delivered to organs at risk contributes to the occurrence of a specific late symptom 
which affects quality of life, and how the relationship may be described best by radiobiological 
modeling.  
Methods: We identified 789 eligible gynecological cancer survivors from the Stockholm and 
Gothenburg regions, treated with pelvic radiation therapy alone or as part of combined therapy 
in 1991 to 2003. A control group of 478 women matched for age and residence was selected 
randomly from the Swedish Population Registry. In 2006 data were collected by means of a 
study-specific, validated postal questionnaire including 351 questions on symptoms from the 
pelvic region, demographics, co-morbidities, psychological and quality of life issues. Details 
about treatment techniques were retrieved from medical records. Participation rate was 78 
percent (N=616) for cancer survivors and 72 percent (N= 344) for control women. Dose-volume 
data for 519 survivors (84 percent), and organs at risk were extracted from the treatment 
planning system for calculation of dose distribution. The data were used for fitting different 
radiobiological models. 
Results: The median age for cancer survivors was 66.0 years and the median follow-up time 
after ending radiation therapy was 74 months (range 26 to 179 months). The most common 
diagnosis was endometrial cancer (59 percent) followed by cervical cancer (23 percent). 
Surgery was part of treatment in 90 percent of the survivors. Cancer survivors reported a higher 
occurrence of symptoms from all studied normal tissues (i.e., symptoms from the anal-sphincter 
region, bowel, urinary tract, pelvic bones, lower abdomen and legs as well as symptoms related 
to sexuality) compared to controls. The highest age-adjusted relative risk (RR) 12.7 (95% CI: 
4.0-40.3) was found for the symptom ‘emptying of all stools into clothing without forewarning’ 
with a prevalence of 12 percent among survivors and 0.9 percent among control women. 
Among the 70 cancer survivors reporting ‘emptying of all stools into clothing without 
forewarning’ the symptom negatively affected quality of life in 51 of the survivors (74 percent). 
This symptom kept the survivors from going to parties (RR 11.8; 95% CI 6.6-21.1), from 
traveling (RR 9.3; 95% CI 5.3-16.5), affected their ability to work (RR 7.9; 95% CI 3.8-16.4) 
and hindered their sexual activity (RR 9.2; 95% CI, 4.8-17.6). 
Mean absorbed doses exceeding 50 Gy to the anal-sphincter region, the rectum, the sigmoid 
and the small intestines were related to the occurrence of ‘emptying of all stools into clothing 
without forewarning’. After adjusting for risk factors such as birth weight over four kg, heart 
failure and gluten and or lactose intolerance, mean absorbed doses over 45 Gy to the anal-
sphincter region and over 50 Gy to the sigmoid were related to the symptom. 
The dose-volume effect relationships for the organs at risk related to ‘emptying of all stools into 
clothing without forewarning’ were further explored and the dose-response parameters for the 
Relative Seriality, the Lyman and gEUD models were estimated. The best fit was for the 
sigmoid, with the highest AUC and γ50. The volume parameters indicate that the anal sphincter 
and small intestines behave serially while the rectum behaves parallel. The sigmoid has a 
mixed serial and parallel behavior. 
Findings: Gynecological cancer survivors are at increased risk of ‘emptying of all stools into 
clothing without forewarning’ after pelvic radiation therapy. This symptom which affects social 
functioning is related to mean absorbed external doses to bowel organs and the anal sphincter 
region, of which the dose to the sigmoid is the best predictor of the occurrence of the symptom 
‘emptying of all stools into clothing without forewarning’. 
Implication: Based on our findings dose-restriction to the involved organs at risk may in the 
future prevent this severe socially disabling symptom which today affects one out of ten 
gynecological cancer survivors. 
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1. INTRODUCTION 
The prevalence of long-term gynecological cancer survivors is rapidly 
increasing thanks to early detection and advances in treatment. A significant 
number of these women have received radiation therapy (RT) and will seek 
help for transient or permanent, mild to severe, radiation-induced symptoms, 
i.e., pelvic radiation disease. These symptoms can be mistaken for other 
conditions or simply neglected and it is therefore essential to increase our 
knowledge and awareness of late side-effects after RT in order to provide 
today’s cancer survivors adequate management and help. 
 
Modern RT techniques such as intensity modulated radiation therapy (IMRT) 
allow the radiation dose to conform more precisely to the three-dimensional 
shape of the tumor. Higher radiation doses can be focused on the tumor while 
minimizing the dose to the surrounding normal tissue. In order to take 
advantage of the new planning and delivery techniques, we need to learn 
more about dose-response and dose-volume relationships for clinically 
relevant normal-tissue endpoints. 
 
This study of long-term gynecological cancer survivors treated with 
conventional pelvic RT can add to knowledge and contribute to refinement of 
future treatments thus sparing patients from symptoms affecting quality of life 
(QoL). 
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2.  BACKGROUND 
Gynecological cancer 
 
The gynecological organs consist of the ovaries, the fallopian tubes, the 
corpus and cervix uteri, the vagina and the vulva. The female reproductive 
organs are in close proximity of the urinary bladder, bowel, anal sphincter and 
pelvic bones (Figure 1). In Sweden, gynecological cancer constitutes 12 
percent of all female cancer and approximately 2900 new cases are 
diagnosed annually1. In 2009 1422 cases of endometrial cancer, 740 ovarian, 
437 of cervical, 127 vulvar, 91 uterine sarcomas, 40 fallopian tube and 31 
cases of vaginal cancer were diagnosed. 
 
 
 
 
 
 
 
 
Figure 1. Female reproductive organs 
 
Endometrial cancer 
Endometrial cancer is the most common gynecological cancer disease in 
developed countries, with the highest incidences in North America and in 
Western Europe. In Sweden it is the 5th most common cancer among 
women1. The incidence of endometrial cancer is steadily rising as life 
expectancy is increasing, and the disease mostly affects postmenopausal 
women. The median age at diagnosis is 63 years, rarely affecting women 
under the age of 40. 
Long-term exposure of estrogens not counterbalanced by the presence of 
progesterone is the most widely accepted hypothesis on the etiology of the 
majority of endometrial cancers, the type-I endometrial carcinoma2. The 
‘unopposed estrogen hypothesis’ can explain most of the identified risk 
factors including obesity, early menarche and late menopause, nulliparity and 
hormone replacement therapy3. The use of Tamoxifen also carries an 
increased risk4. The less common type-2 endometrial carcinomas (high 
grade, non-endometrioid cell type) seem to be unrelated to estrogens and 
carry a worse prognosis. About five percent of endometrial cancer is 
considered to be hereditary and linked to hereditary nonpolyposis colorectal 
cancer5 
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Endometrial cancer is usually diagnosed at an early stage when still limited to 
the uterus, since it most often presents with vaginal bleeding. Survival rates 
are therefore generally high. Sweden had the highest 5-year survival rate 
among Nordic patients diagnosed in 1999 to 2003, 89 percent6. 
In Sweden, gynecological cancer is staged according to the International 
Federation of Gynecology and Obstetrics (FIGO)7. The FIGO staging for 
carcinoma of the endometrium, cervix and vulva has recently been revised8. 
Endometrial cancer is staged surgically and lymphadenectomy is part of the 
staging procedure. Around 10 percent of women with presumably stage I 
disease have lymph node metastases, i.e. a stage III. No therapeutic benefit 
of lymphadenectomy has been proven according to a meta-analysis by 
Cochrane9 including 1945 patients. Lymphadenectomy was associated with 
increased risk of surgically-related systemic morbidity and lymph edema or 
lymphocyst development. Against this background and the wide use of 
adjuvant RT, lymphadenectomy has not been routinely performed in Sweden. 
The standard treatment for endometrial cancer includes primary surgery, 
typically consisting of hysterectomy and bilateral salpingo-oophorectomy. 
Adjuvant EBRT combined with vaginal brachytherapy (BT) has until recently 
been widely used in Sweden for alleged stage I patients. 
Preoperative intrauterine BT was previously frequently used in stage I 
cancer10. The rationale for using preoperative BT was to reduce the risk of 
tumor spread during surgery. Initially a low dose-rate packing method with 
226Radium was used. The preoperative BT was gradually replaced with 
primary surgery during the 1990s in order to be able to allocate women to 
different prognostic groups and thereby avoid overtreatment. The method is 
still an effective curative treatment in women unfit for surgery. 
Several randomized controlled trials (RCTs) have addressed the benefit of 
adjuvant RT in early stages of endometrial cancer. A systematic review by 
Cochrane including four trials with 1779 patients compared adjuvant RT 
versus no RT in stage I endometrial cancer following surgery11. The analysis 
showed a tendency toward improved survival in women with stage I and high 
risk of recurrence, i.e., stage IC and grade 3 who received adjuvant pelvic 
EBRT. This may support the use of adjuvant EBRT in this setting. 
Women with low risk of recurrence, grade 1-2 endometrioid cancer stage IA-
IB, is treated with surgery alone12. For women with intermediate risk of 
recurrence either observation or vaginal BT is warranted13, 14. 
The effect on survival of postoperative adjuvant chemotherapy has recently 
been assessed by Cochrane15. Pooling of survival data from 2197 women 
showed a significant overall and progression-free survival benefit for 
postoperative platinum-based chemotherapy. The data suggests an additive 
value in combination with RT, but may also be an alternative to RT. 
Concurrent chemoradiotherapy16 is currently being explored in an RCT 
(PORTEC 3). Patients with advanced stages of endometrial cancer often 
receive a combination of surgery, RT and chemotherapy. 
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Cervical cancer 
The organized population-based screening in Sweden, introduced in the 
1960s, leading to early detection of precancerous lesions and their treatment, 
has greatly reduced the incidence and mortality of cervical cancer, the second 
most common cancer among women in the world. Median age at diagnosis is 
59 years and one quarter is younger than 40 years of age1. The majority of 
women are diagnosed with an early stage of disease. The 5-year survival rates 
for Nordic patients diagnosed in 1999 to 2003 are quite comparable across the 
populations, with ratios varying between 64 and 68 percent17. The survival rate 
exceeds 85 percent among patients younger than 50 years of age, with survival 
steadily decreasing as age increases. 
 
A persistent infection with high risk HPV is the most important etiological 
factor18. HPV vaccines offer a promising option for preventing cervical cancer, 
including other HPV-related tumors such as vaginal and vulvar cancers19. 
Smoking and other genital infections are also considered to be risk factors20. 
 
The treatment of cervical cancer is determined by the stage of disease. The 
FIGO staging for cervical cancer is based on clinical evaluation8. 
 
Microinvasive cervical cancer (FIGO stage IA1 and IA2) is usually cured by 
cone biopsy, trachelectomy or simple hysterectomy. Surgery and RT seem to 
be equally effective in FIGO stage IB or IIA cervical cancer21. Radical 
hysterectomy and pelvic lymph node dissection (PLND) is usually the treatment 
of choice due to the risk of side effects by RT22, 23. Beneficial effects of nerve-
sparing surgery on bladder, gastrointestinal and sexual function have been 
reported24-26. Radical trachelectomy after PLND can be considered in women 
wishing to preserve fertility27. 
 
Preoperative intrauterine BT was previously frequently used in Sweden for 
early stages (stage IB-IIA) of cervical cancer. Initially a manual technique with 
226Radium applicators was used and patients were treated according to the 
individualized Stockholm method described by Kottmeier in 196428. The 
manual technique included a combination of an intrauterine tube (43-70 mg 
Radium) and a vaginal applicator (50-70 mg Radium). In Stockholm, an after-
loading technique with 137Cesium gradually replaced the manual technique in 
the early 1990s, using a circular-shaped vaginal applicator and a uterine 
applicator in the Selectron System29. Patients were treated with two 
uterovaginal intracavitary treatments with a three-week interval, followed by 
surgery (or in surgically unfit patients with EBRT four weeks later). The total 
dose to Point A30 was 45 Gy for squamous cell carcinoma and 48 Gy for 
adenocarcinomas. Patients treated with intracavitary BT and receiving EBRT 
had a central shield with a width of four cm. The prescribed dose to the 
shielded volume was adjusted in order not to exceed a total dose of 50 Gy to 
the rectum and 60 Gy to the urinary bladder. An additional prophylactic 
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paraaortic field with total dose of 40 Gy (1.6 Gy per fraction) was prescribed to 
patients with pelvic lymph node metastasis until 2000. The Stockholm 
treatment results of preoperative EBRT in FIGO stage IB-IIA cervical cancer 
have been published by Beskow et al31. Pathologic complete remission after 
preoperative intracavitary BT of cervical cancer stage IB and IIA is a strong 
prognostic factor for long-term survival. Similar favorable results after 
preoperative EBRT have recently been published by a French group32. 
 
Women with high-risk for recurrence such as lymph node metastasis, 
parametrial invasion and positive resection margins have a recurrence rate of 
nearly 40 percent after surgery33. These women are treated with concomitant 
chemoradiation which has been shown to increase progression-free survival 
from 63 to 80 percent and overall survival from 71 to 81 percent34. 
 
The role of adjuvant treatment for women with stage IB with intermediate risk of 
recurrence following surgery is debated, due to the risk of overtreatment and 
the lack of proven survival benefit. The risk of recurrence among patients with 
intermediate risk factors, such as deep stromal invasion, large tumor size and 
lymph-vascular space invasion varies between 2 to 31 percent at three years35, 
36
. In all, 277 stage IB cervical patients with two or more intermediate risk 
factor cervical patients were randomized to observation after surgery or 
adjuvant EBRT. A long-term follow-up showed a statistically detectable 
reduction in risk of recurrence and prolongation of progression-free survival, 
but improvement in overall survival did not reach statistical significance36. 
 
For locally advanced (FIGO stage IB2-IVA) weekly intravenous cisplatinum 40 
mg/m2 combined with concomitant EBRT is established a standard treatment. 
The latest published meta analysis based on 13 RCTs comparing concomitant 
chemoradiation versus the same RT demonstrated a six percent improvement 
in 5-year survival (p<0.01) but at the price of increased acute hematologic and 
gastrointestinal toxicity. Data were too sparse for an analysis of late toxicity37. 
The role of neoadjuvant chemotherapy has yet to be determined and currently 
two ongoing RCTs are comparing neoadjuvant chemotherapy following surgery 
versus concomitant chemoradiation. 
 
 
Ovarian and Fallopian tube cancer 
Around 90 percent of malignant ovarian tumors originate from the coelomic 
epithelium38. The estimated number of new cases worldwide is 225 000 
annually and the highest incidence of ovarian cancer is found in North America 
and Northern and Western Europe39. Epithelial ovarian cancer is the leading 
cause of death from gynecological cancer in these continents reflecting the 
difficulties of detecting the disease in early stage and the development of 
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chemoresistent disease. Population-based relative 5-year survival is below 50 
percent17. The median age at diagnosis is 65 years1. 
 
Etiology is multifactorial reflecting the heterogeneity of epithelial ovarian 
cancer. Increasing age, early menarche, late menopause, nulliparity and 
endometriosis are associated with an increased risk of epithelial ovarian 
cancer. A decreased risk is associated with the use of oral contraceptives and 
breast feeding. A hereditary component is found in at least ten percent of the 
cases, most commonly BRCA1 or BRCA 2 mutations40. 
 
Fallopian tube cancer is a rare disease. Studies indicate that the fallopian tubes 
may be the origin of some epithelial ovarian cancer41. Fallopian tube cancer is 
managed in a similar manner as epithelial ovarian cancer. 
Both ovarian and fallopian tube cancer is surgically staged according to the 
FIGO classification42. Primary cytoreductive surgery followed by postoperative 
chemotherapy with paclitaxel and carboplatin is the standard treatment for 
ovarian cancer43. Whole abdominal radiation therapy is rarely used due to 
severe late gastrointestinal side-effects, but can be used in the palliative 
setting44. 
 
 
Uterine sarcoma 
Uterine sarcomas are rare and highly malignant gynecological diseases that 
account for three percent of uterine cancers. It affects around 100 Swedish 
women annually with a median age of 55 years1. Their rarity and histological 
diversity contributes to the lack of consensus on prognostic risk factors and 
optimal treatment45. The disease originates from the muscle cells in the uterus 
or from supporting tissues surrounding the uterus. The prognosis varies and 
depends on the type of mesenchymal tumor and stage of disease. The 5-year 
survival rate is reported to be between 17 and 55 percent46-48. 
 
Until recently the FIGO classification for endometrial carcinoma has been used 
to stage uterine sarcomas but in 2009 a new FIGO classification has been 
specifically designed for uterine sarcomas, due to their divergent biologic 
behavior. Carcinosarcomas has recently been reclassified as dedifferentiated 
form of endometrial carcinoma and should be staged as endometrial cancer. 
Treatment is similar to high-risk endometrial cancer. Leiomyosarcomas 
composed of malignant uterine smooth-muscle cells is the most common 
subtype of uterine sarcoma, after excluding carcinosarcomas. They are 
associated with poor prognosis even when diagnosed at an early stage. 
Treatment includes hysterectomy and the ovaries can often be preserved. The 
role of adjuvant RT is not fully established49. Endometrial stromal tumors are 
divided into low-grade endometrial stromal sarcomas and undifferentiated 
sarcomas50. Low-grade endometrial stromal sarcomas have a favorable 
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prognosis and are often sensitive to progestational treatment. In contrast, 
undifferentiated sarcomas are highly aggressive and have a poor prognosis. 
Treatment for endometrial stromal tumors consists of primary surgery including 
hysterectomy and bilateral salpingo-oophorectomy. The benefit of adjuvant 
pelvic EBRT is unclear although studies suggest improved local control without 
improvement of disease free survival49, 51. For patients with advanced disease 
treatment options include surgery in combination with chemotherapy and pelvic 
EBRT. 
 
 
Vaginal cancer 
Primary vaginal cancer, with no involvement of the cervix or the vulva, is a rare 
disease and most published results are based on small studies retrospectively 
collected. Vaginal cancer occurs most often among women older than 60 years 
of age. The etiology of vaginal cancer is, like cervical cancer, linked to 
persistent infection with high-risk HPV18. Overall survival is approximately 50 
percent52. Vaginal cancer is usually treated with a combination of EBRT and 
vaginal BT, with or without chemotherapy52. Surgery is an option for small 
lesions in stage I. 
 
 
Vulvar cancer 
Vulvar cancer accounts for five percent of gynecological cancers with less than 
100 new cases every year in Sweden1. A majority of women are at least 70 
years of age at diagnosis 53. The FIGO staging classification is surgical. The 5-
year survival rate is favorable in Stage I, near 80 percent, but poor for more 
advanced disease 54. 
 
Two separate pathways of disease development have been found; the first is 
associated with high-risk HPV and affects younger women and the second is 
associated with lichen sclerosis or squamous cell hyperplasia and is 
independent of HPV55. 
 
Radical vulvectomy with bilateral inguinal lymphadenectomy has so far been 
the predominant way of treating vulvar cancer, but due to significant morbidity a 
more individualized approach has developed56. Treatment for more advanced 
stages of disease is individualized and usually involves a combination of 
surgery, RT and chemotherapy. A systematic review by Cochrane evaluated 
the efficiency and safety of neoadjuvant chemoradiation and the results, based 
on five non-randomized trials, showed an improvement in operability at the 
expense of increased severe toxicity57. 
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Radiation therapy 
Radiation therapy (RT) has been used for many years in the treatment of 
gynecological cancer diseases. Shortly after the discovery of Radium in 1898, 
treatment for gynecological cancers was introduced58. There are two major 
ways of delivering ionizing radiation therapy; EBRT and BT. 
 
External beam radiation therapy 
External beam radiation therapy (EBRT) was initially given by using X-ray 
devices or Cobalt-60 machines. Due to poor penetration, a wide penumbra and 
risk of skin reactions, most clinics have replaced these devices with linear 
accelerators which produce electrons between 4 and 20 MeV and photons with 
energy of 6 to 20 MV. A few clinics have been equipped with racetrack 
accelerators that can deliver photons of 50 MV. Particles such as protons and 
light ions are also used to irradiate cancer cells. The radiation dose produced 
by these particles is very precisely disposed due to low lateral scatter and the 
sharply defined dose maximum, the Bragg peak (Figure 2). 
 
 
 
 
 
 
 
Figure 2. Proton Bragg peak 
 
Treatment volumes and organs at risk need to be carefully defined. 
Prescribing, recording and reporting of photon beam therapy is performed 
according to recommendations by International Commission on Radiation Units 
and Measurements59. Pretreatment Computerized Tomography (CT), Magnetic 
resonance imaging (MRI) and Positron emission tomography (PET) can be 
used to identify tumour target volume and surrounding normal tissues. By 
contouring target areas in consecutive slices, three-dimensional volumes were 
constructed, and the absorbed doses were calculated. The treatment fields 
used to be shaped by manually placed customized lead blocks, as illustrated in 
Figure 3. 
 
Figure 3. Pelvic fields with lead blocks 
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Modern treatment machines are equipped with integrated computerized Multi 
Leaf Collimators (MLC) that forms the treatment fields according to the 
treatment plan (Figure 4). 
 
 
 
 
 
 
 
 
Figure 4. Multi Leaf Collimator 
 
The dose distribution can be further improved by IMRT or RapidArc, which 
uses non-uniform beam intensity patterns. IMRT can produce concave shaped 
isodose distributions and it has a sharp fall off near the edge of the treatment 
volumes. (Figure 5). 
 
 
 
 
 
 
 
 
Figure 5. IMRT dose plan 
 
Proper immobilization and repeated image guidance during treatment course is 
necessary to ensure good quality of the EBRT. 
 
 
Brachytherapy 
Brachytherapy (brachy; Greek for short distance).is RT with short range where 
the radioactive source is put directly in the tumour (interstitially) or inside a 
hollow organ (intracavitary). The first treatments with BT were performed 
already during the first decades of the 20th century. The Stockholm method for 
BT was developed at Radiumhemmet and the first treatment results on cervical 
cancer were published in 192960. The discovery of artificial radioactivity shortly 
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before World War II paved the way for the use of radionuclides such as Iridium 
and Cesium. Remote afterloading devices were developed to overcome 
radiation protection problems in the handling of the radioactive substances. 
 
The dose is prescribed to an isodose encircling a small target volume and the 
dose distribution is very heterogeneous, being minimal at distance from the 
radioactive source and much higher at its center. The dose is delivered 
continuously with a short total treatment time ranging from minutes to hours. 
Low dose rate BT (LDR BT) Cesium delivers 0.4-2 Gy/hour and high dose rate 
BT (HDR BT) Iridium delivers 12 Gy/hour or more. A three-dimensional image-
based approach for delineation of gross tumor volume and clinical tumor 
volume and organs at risk provides optimization and tailored BT dose 
planning61. 
 
 
Radiobiology 
The Linear-Quadratic (LQ) model, which was first proposed by Douglas and 
Fowler in 197662, considers radiation damage as a result of one of two 
separate, but concurrent processes. First, the amount of damage varies 
linearly with dose in the single-hit process in the α-component. Secondly, the 
amount of damage varies with the square of the dose in the β-component63. 
The total damage created by the dose d, is given as; 
 
αd + βd2 
In terms of clinically observable effect it is more convenient to describe the 
effect as the surviving fraction (S) of cells, which decreases as an exponential 
function of the total damage; 
 
S = exp (-αd - βd2) 
 
 
 
 
 
 
ln(S) = -αd - βd2 
 
Introduction of the number of fractions, N; 
 
-ln(SN) = Nαd + Nβd2 
 
 
Figure 6. Effect of high dose rate and low 
dose rate on cell survival curve 
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Biological effective dose (BED) is derived by dividing both sides with α; 
 
BED = Nd [1 + d/(α/β)]64 
 
This equation applies well in the case of N well-spaced fractions delivered to 
tissues with no or little growth (most normal tissues) during the time it takes to 
deliver all N fractions. For rapidly growing normal tissues and tumors one has 
to take the repopulation into account. 
 
Tissue-specific α/β-ratio reflects the shape of the dose-response curve. 
Normal tissues are considered to have α/β-ratios around 3 Gy. Rapidly 
growing normal tissues and tumors are considered to have values around 10 
Gy (Figure 7). 
 
 
 
 
 
Figure 7. Cell survival curves for α/β ● = 3, ● = 4, ● = 10 
Lower dose per fraction and an increased number of fractions lead to a 
sparing effect which is most pronounced in tissues with slow proliferation. 
Time between two fractions must be at least six hours in order to allow 
sublethal damages to repair. Continuous LDR BT can show a similar sparing 
effect as seen with hyperfractionation. This is the rationale for giving pelvic 
EBRT in several fractions of 1.6-2.0 Gy. 
 
The effects on cells are described by the 4 R's of radiobiology: 
Repair of sublethal DNA damage. This is thought to be more effective in 
normal cells as opposed to cancer cells. Redistribution into phases in which 
cells are more radiosensitive. Repopulation through an increase in cell 
division that is seen at some point in time after radiation is delivered. 
Deoxygenating of hypoxic regions where cells are thought to be resistant to 
radiation (Figure 8). Presence of oxygen is an essential component in cell 
killing65. 
 
 
 
 
 
Figure 8. Cell survival curves for hypoxic and normoxic cells 
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Development of radiotherapy-induced side effects 
The process of acute radiation damage starts immediately after exposure. 
Unrepaired or misrepaired DNA damage usually leads to cell death within the 
first or subsequent cell divisions. Cell death may also occur through 
apoptosis. Activation of different cellular signaling cytokines leads to 
inflammatory responses. The acute effects are most pronounced in tissues 
with high cell turnover such as cells outlining the gastrointestinal tract and the 
skin. Symptoms develop when these cells no longer can be replaced by the 
action of stem-cells and therefore most symptoms do not show immediately66. 
Acute side-effects are considered to be symptoms that develop during the 
course of the treatment or shortly afterwards and remain for a maximum of 
three months and then subside. The symptoms can remain beyond three 
months with unchanged strength or even progress. Symptoms present at 
three months after completed RT are considered to be late side effects. 
Severe acute side effects are considered to be predictive of the risk of having 
late side effects; consequential late effects67. 
The degree and extent of the radiotherapy-induced toxicity depends on type 
of radiation, dose per fraction68, total dose, dose rate, total treatment time69 
and irradiated volume. The mechanism leading to the side-effects is 
multifactorial, including patient characteristics70, 71 and radiogenomics. 
Ionizing radiation not only induces a direct cell killing but also induces 
activation of cytokines and growth factors, which could be potential targets for 
preventing or treating late side-effects 64, 66, 72-74. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mechanisms for developing long-term symptoms 
 
Risk factors for developing radiotherapy-induced toxicity 
The development of radiotherapy-induced toxicity can be influenced by many 
factors. Radiation treatment related factors such as the total dose and dose per 
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fraction; fractionation schedule, decides the amount of damage but also the 
capacity for repair of sublethal DNA-damage63. Irradiation with protons will 
create more extensive damage compared to electrons due to the larger 
biological effect75. Factors involving the tumor and normal tissue in close 
proximity to the tumor are of the utmost importance as are additional treatment 
modalities. 
 
Radiation treatment related factors 
• Total dose 
• Dose per fraction 
• Fractionation schedule 
• Total treatment time 
• Irradiated volume 
• Type of radiation 
Tumour related factors and factors involving irradiated normal tissue 
• Size 
• Grade 
• Stage 
• Histology 
• Location 
• Functional reserve in irradiated organ 
• Structural organization of irradiated organ76 
Other treatments administered in sequence or concomitantly 
• Surgery 
• Chemotherapy 
• Biological treatment 
Patient related factors 
• Age 
• Smoking 
• Diabetes mellitus 
• Cardiovascular disease 
• Inflammatory bowel disease 
• Connective tissue disorder 
• Injuries affecting pelvic floor 
• Other co-morbidities 
• Genetic susceptibility towards radiation induced injury 
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Several studies show different aspects of late side effects; Cozzarini et al 
retrospectively scored late genitourinary toxicity according to CTCAE v3 in 742 
prostate cancer survivors after pelvic EBRT77. Acute Grade 2 or more was 
found to be predictive for the development of late Grade 3 toxicity with a 
prevalence of 16 percent compared to 10 percent, supporting the theory of 
consequential late effects67. Conventional EBRT in the Cozzarini study carried 
a risk of 21 percent compared to conformal EBRT; 11 percent, illustrating the 
effect of treatment technique. Survivors with hypertension had an 8-year risk of 
Grade 3 sequelae of 18 percent compared to normotensive survivors with a 
risk of 10 percent. These results support the idea of negative impact of co-
morbidities64, 78 
In a retrospective analysis of 806 women treated with adjuvant postoperative 
pelvic EBRT for endometrial or cervical cancer, Huscher et al assessed the 
rate of late small bowel toxicity79. The 5- and 10-year toxicity rates were four 
and seven percent. Survivors older than 60 years of age had a doubled risk of 
developing severe late small bowel toxicity with a Hazards Rate of 2.2. Daily 
fractions of 1.8 Gy or less led to significantly lowered risk of bowel damage risk. 
Again severe acute toxicity was predictive of late toxicity, supporting the idea of 
consequential late effects67. 
Eifel et al retrospectively reviewed actuarial risk of complications in 1784 
irradiated stage IB (FIGO) cervical cancer survivors over a period of 20 years80. 
Complication rate at 3 years was 7.7 percent and at 5 years 9.3 percent with 
symptoms progressing with time. Risk of fistula formation and bowel 
obstruction was doubled in survivors who had prior abdominal surgery. An 
increased cumulative risk was seen for women who were young at the time of 
treatment and may be a result of long survival and prolonged time under risk. 
 
 
Instruments for recording late side effects and quality of life 
There is a wide variety of instruments for the recording of late side effects 
after radiotherapy. Many of them combine multiple signs and symptoms into a 
single grade leading to a loss of specificity. 
The French Italian Glossary (FIG)81 was developed in the 80s to record 
radiation side effects regardless of treatment strategy. The complications after 
treatment are described in terms of five degrees of increasing severity from 0 
to 4 for 14 organs and/or normal tissues contained in the female pelvis. Each 
grade is further subdivided into subgroups, each of which describes different 
symptoms and signs. As a result the FIG mixes various endpoints for the 
same organ, early and late morbidity are not separated and both subjective 
and objective effects are combined. 
In 1995 the RTOG and the EORTC organizations agreed on a common 
system for toxicity criteria82. The system included five degrees of injury within 
17 organ categories, with the Grade 0 indicating no injury and Grade 5 
meaning that the effect was lethal. 
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The LENT (Late Effects of Normal Tissue) SOMA (Subjective, Objective, 
Management, Analysis)83 grading system is more detailed than the 
RTOG/EORTC toxicity criteria. Grade 0 indicates no toxicity. Grade 1 
includes symptoms normally reported by the patients (subjective category); 
Grade 2 includes what is reported by a physician or by clinical examination 
(objective category); Grade 3 includes steps to alleviate symptoms 
(management category); Grade 4 includes items given by more advanced 
diagnostics (analytic category). Although providing much information, it has 
been found to be time consuming and difficult to use routinely outside 
controlled studies. 
By incorporating LENT SOMA items the CTCAE v3 (Common Terminology 
Criteria for Adverse Events version 3)84 of 2003 was developed. Among the 
newly adopted principles is the merging of acute and late effect criteria which 
will be used without predetermined time-base designation and the fact that it 
is applicable to all treatment modalities. 
TAME85 which was introduced in 2007 is the most recently developed system 
made for summarizing the total toxicity caused by cancer treatment. Short-
term, acute, Toxicity, Adverse long-term, late, effects, and Mortality risk are 
summarized into End results85. 
The use of multiple scoring systems for adverse events has created 
difficulties when trying to compare results between studies and institutions. 
 
Traditionally, the primary endpoints of an evaluation of medical treatment 
have only included improvement in clinical outcome, cure and survival, and 
not the QoL. However, the assessment of patient-related outcomes has 
become a more essential part of the evaluation in gynecological oncology. 
The Medical Outcomes Study Short Form-36 (SF-36)86 is a questionnaire that 
measures eight health domains and is often used in health surveys. 
The European Organization for Research in the Treatment of Cancer has 
developed the EORTC QLQ-3087, which measures physical, emotional and 
social functioning, disease-specific symptoms, economic impact and global 
QoL. This questionnaire can be combined with disease-specific modules for 
endometrial, cervical and ovarian cancer. 
The Functional Assessment of Cancer Therapy questionnaire (FACT-C)88 
contains questions covering four areas of well-being; Physical, Social and 
Family, Emotional and Functional. Two subscales are specific to cervical and 
ovarian cancer. 
 
 
Radiation induced symptoms and quality of life 
General side-effects of RT include fatigue, nausea, nutritional problems, skin 
reaction and susceptibility to infections. 
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Recent studies have demonstrated that gastrointestinal symptoms after 
curative pelvic are far more common than generally believed89-92. Symptom 
occurrence and intensity can differ depending on if and how survivors are 
asked. Many of the symptoms are thought to be embarrassing and therefore 
questions may not be asked about them and the symptoms may not even be 
mentioned93. Permanently changed bowel functioning is found in up to 80 
percent of cancer survivors following pelvic RT. 
One of the most common symptoms is loose stools with an incidence from 
around 15 to 50 percent94, 95. The underlying mechanism includes disturbed 
small bowel function, accelerated bowel transit, altered bile contents, 
pancreatic malfunction and aggravation of existing inflammatory bowel 
disease96. Overgrowth of bacteria may enhance the problem with bloating and 
foul smelling flatulence97, 98. 
Defecation urgency has been reported in between 45 and 55 percent of 
survivors after pelvic RT99-103. The urgency can be a result of decreased 
rectal compliance which reduces the ability to store the fecal content. Urgency 
can also be caused by local inflammatory processes and additional 
malignancies such as rectal cancer. 
Fecal incontinence defined as ‘involuntary loss of liquid or solid stool that is a 
social or hygienic problem’104 is said to affect from 20 to 50 percent of 
survivors102, 103, 105-107. The mechanism leading to fecal incontinence includes 
changes in anal resting tone, squeeze pressure and rectal compliance93, 108 
and also decreased perception of rectal sensation due to impaired efferent 
innervations109. The consistency of the stool is important for preservation of 
continence with loose stools leading to higher risk for incontinence106, 108. 
Flatulence is produced by bacterial fermentation of food and glycoproteins in 
the colon. Patients complaining of gas symptoms have an impaired handling 
of the intestinal contents with segmental pooling and focal gut distension. 
Disrupted gas transit can result in bloating110, 111. 
Abdominal pain has been reported in up to 30 percent of all survivors after 
pelvic RT112. Several different mechanisms can contribute to the development 
of pain such as bowel obstruction due to impaired motility and strictures and 
by bowel spasms100, 113, 114. 
 
The urinary tract has been regarded as less radiosensitive compared to the 
bowel115 and reports on prevalence of specific urinary symptoms among 
gynecological cancer survivors are scares. Most studies show that late post-
radiation urinary morbidity continues to progress decades after RT116. 
A prevalence of 8 to 25 percent of genitourinary toxicity including urinary 
urgency, recurrent episodes of urinary infections and minor incontinence has 
been reported in survivors after adjuvant RT in endometrial cancer survivors 
92
, 
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. Higher risk of late urinary side effects has been reported among cervical 
cancer survivors which is probably attributable to higher doses of radiation117. 
The vascular endothelial cells are damaged which leads to perivascular 
fibrosis, vascular occlusion and focal bladder ischemia by six to twelve 
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months. The smooth muscle is replaced by fibroblasts and collagen resulting 
in decreased bladder compliance and decreased volume. Long-term toxicity 
includes cystitis with pain, urinary urgency and haematuria, urinary 
incontinence, decreased storage capacity, voiding dysfunction, urethral 
stenosis and fistula formation115. 
 
Feltl et al reported that 0.44 percent of gynecological cancer survivors 
developed painful micro fractures in the pelvic bones caused by 
osteoradionecrosis at a median follow-up time of seven years after pelvic 
RT118. In the study by Ikushima 11.4 percent of the survivors developed 
painful insufficiency fractures in the pelvic bones. Risk factors were 
preexisting osteoporosis, age, smoking and low body weight119 
 
Resection of pelvic lymph nodes and vessels together with gravitational 
influence on lymphatic flow can lead to lymphatic congestion – lymph edema. 
Secondary toxicity can result in skin breakdown, erysipelas, pain, neuropathy 
and myopathy. Survivors frequently describe the lymph edema symptoms as 
heaviness, and swelling120. 
 
Post-treatment leukemia has been found to be increased in survivors treated 
with pelvic RT. The risk peaked at five to ten years and remained elevated for 
ten to fifteen years after completed treatment. No increase in myeloma has 
been reported121. 
 
In recent years there has been an increasing interest in measuring QoL as 
part of clinical trials 122 also in long-term cancer survivors 123. QoL is said to 
be a subjective perception which embraces all dimensions of the health 
experience 124. The World Health Organization states that QoL is the 
individuals’ perception of that person’s position in life in the context of the 
culture and value system in which he or she lives and in relation to the 
individual’s goals, expectations, standards and concerns 125. 
Available studies on QoL in long-term gynecological cancer survivors lead to 
the conclusion that more research is needed126. Studies have shown that QoL 
is decreased more often in survivors treated with RT than in those treated 
with surgery or Chemotherapy. More than one treatment modality, long 
treatment duration and low socioeconomic status enhance the risk of 
decreased QoL127. 
 
 
Radiobiological modeling and normal tissue complications 
The principal aim of radical RT is to achieve the highest tumor control 
probability (TCP) and at the same time to minimize the normal tissues 
complication probability (NTCP) in order to have the lowest complication rate. 
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Dose-volume response models or NTCP models can be used as tools for the 
optimization of RT treatment plans in order to minimize toxicity128. The 
probability curve has an S-shape as illustrated in Figure 10. The models aim 
to reduce complicated dosimetric and anatomical information to a single risk 
measure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Normal Tissue Complication Probability, NTCP 
 
Commonly accepted tolerable doses to normal tissues have mostly been 
derived empirically and can only serve as estimates of radiation tolerance. 
The paper by Emami et al129 is still considered to contain the standard 
recommendations for normal tissue tolerance in RT. Some of the presented 
tolerance doses were based on experimental and clinical investigational data. 
Others were based on less solid data, but are still considered to be relatively 
reliable. A few dose data were based on individual clinicians’ experience and 
can be a result of extrapolating existing data. These doses have provided 
assistance for estimating complication probabilities in tissues that receive a 
uniform dose to a part of the tissue and no dose to the remainder. Emami et 
al presented tolerance doses (TD) for increasing parts of each assessed 
organ with a five (TD 5/5) and 50 (TD 50/5) percent risk of developing 
specified clinical end-points within five years after treatment. 
The Emami data for gastrointestinal organ including the small bowel, the 
colon and the rectum was hard to find due to lack of sufficient dose 
information or problems to estimate organ volume. TD 5/5 for the whole small 
bowel has been estimated to 40 Gy and for one-third of the organ volume to 
45-50 Gy for development of obstruction, perforation and fistula. TD 5/5 for 
whole colon has been estimated to 45 Gy and TD 5/5 for one-third of the 
volume to 55 Gy. For the rectum no volume effect was seen and the TD 5/5 
was estimated to 60 Gy. The estimated TD 5/5 data for the whole urinary 
bladder was 65 Gy compared to one-third of the volume; which was 80 Gy. 
The TD 50/5 data for the urinary bladder has been assumed to be in the order 
of 80 Gy. Whole femoral head had a TD 5/5 of 52 Gy and 50/5 of 65 Gy. 
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A limited number of available organ specific dose-volume and outcome data 
are presented in the paper by Marks et al128 although they are accompanied 
by multiple caveats. 
Two-dimensional dose-volume histograms (DVH) from specific organs at risk 
can be extracted from the treatment planning system. Information including the 
maximum, the minimum and the mean dose, the standard deviation of dose, 
and the volume of studied organs can also be extracted. 
In 1985 Lyman et al suggested an empirical mode, which used available 
tolerance dose data to estimate the complication probability. The relation 
between a dose of uniform radiation and the probability of the effect formed a 
probit function, an S-shaped curve characterized by the dose that corresponds 
to 50 percent complication probability after uniform irradiation of the reference 
volume, TD 50, and the slope of the curve130. The Lyman model also describes 
the volume effect. 
In 1991 Kutcher et al combined the probit function with the DVH reduction 
method for transforming non uniform DVHs into equivalent uniform DVHs to 
account for the inhomogeneously irradiation of the organ131. The Emami 
tolerance data in combination with Lyman’s model resulted in the LKB (Lyman 
Kutcher Burman) model in 1991 which provided estimated normal tissue 
complication probabilities for any combination of dose and irradiated volume for 
the normal tissues and end points considered132. 
In 1997 Niemierko defined the generalized Equivalent Uniform Dose (gEUD) 
concept. The gEUD is a way of ‘summarizing’ the whole dose distribution in a 
volume of interest to a single figure and is the most common expression for 
OAR. The gEUD is the dose that supposedly, if given uniformly to the entire 
organ, will cause the same complication rate as the true dose distribution133. 
The RS (Relative Seriality) model presented by Källman et al in 199276, 
assumes that organs have combinations of serial and parallel functional 
subunits. One of the model parameters describes the ratio of serial subunits 
to all subunits of the organ; the endpoints relative seriality, hence the name. 
In an organ with serial organization (the spinal cord), a high dose to a very 
small volume can result in serious toxicity, which is an effect of maximum 
dose. In an organ with parallel organization (the lung), a low dose to a large 
part of the organ volume can cause side effects, which is an effect of mean 
dose. 
New RT techniques allow the treatment planners to decide which regions of 
the normal tissues that could be spared. The QUANTEC (Quantitative 
Analyses of Normal Tissue Effects in the Clinic) project134 aims to collect all 
available three-dimensional dose/volume and outcome data and to 
summarize them in a clinically useful manner. One of the new concepts is to 
atomize symptoms in an attempt to find specific pathophysiological processes 
that explain the outcome. 
The NTCP models have some limitations. They are based on two-
dimensional DVHs which are not ideal representations of the three-
dimensional dose-volume information since they discard the organ-specific 
spatial information Other limitations are a single pre-treatment CT, differences 
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in fractionation schedules and variance in treatment routines within and 
between clinics.  
Additional difficulties to be overcome in NTCP modeling are the effects of 
different fractionations scheme, the impact of combined treatment modalities 
as chemoradiation, host factors as smoking, co-morbidities and 
radiogenomics, trading of risk between organs. An increased understanding 
of expected toxicity produced by different competing treatment plans may 
guide the radiotherapist in choosing the most optimal one. 
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3. AIM 
The overall aim of this study was to investigate the prevalence of late self-
reported symptoms from normal tissues in the pelvic region among long-term 
gynecological cancer survivors as well as to study how the dose-volume 
distribution of ionizing radiation delivered to organs at risk contributes to the 
occurrence of a late specific symptom affecting QoL  
 
 
Specific aims 
 
To survey the occurrence of physical symptoms among long-term 
gynecological cancer survivors previously treated with pelvic RT and compare 
with control women from the general population. 
 
To investigate how the patient-reported symptom ‘emptying of all stools into 
clothing without forewarning’, impacts self-assessed QoL from a social, 
psychological, sexual, and functional perspectives among gynecological 
cancer survivors treated with pelvic radiotherapy 
 
To investigate the association between mean absorbed dose to the bowel 
and anal-sphincter region after pelvic RT and the occurrence of the symptom 
‘emptying of all stools into clothing without forewarning’. 
 
To assess the dose-volume response relationships between ’emptying of all 
stools into clothing without forewarning‘ and pelvic organs at risk using 
different radiobiological models. 
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4. MATERIAL AND METHODS 
Study population 
In 2005 we identified 1800 women consecutively treated between March 1991 
and December 2003 with curative EBRT for a gynecological malignancy at 
Radiumhemmet, Karolinska University Hospital in Stockholm or at 
Jubileumskliniken, Sahlgrenska University Hospital in Gothenburg. 
The chosen time frame represented the initiation of three-dimensional 
treatment planning with access to electronically stored data, which was a 
prerequisite for the study. The method was introduced in 1991 in Stockholm 
and in 1994 in Gothenburg. The year 2003 was chosen to allow development 
of treatment-related long-term side effects and at the same time to exclude 
the majority of patients who had recurrent disease shortly after treatment. The 
flow chart for inclusion is illustrated in Figure 11. 
 
Figure 11. Flow chart for inclusion. 
1800 gynecological cancer patients treated 
with external pelvic radiation therapy in 
1991-2003 at Karolinska University 
Hospital, Stockholm or Sahlgrenska 
University Hospital, Gothenburg 
Random sample of 486 control women 
from the Swedish Population Registry, 
matched for age and residency 
 
8 did not meet the eligible criteria: 
 
Born before 1927 
Did not understand Swedish 
Had received pelvic radiation therapy 
An introductory letter was sent to 478 
eligible control women 
1011 did not meet the eligible criteria: 
 
497 dead at follow up 
436 born before 1927 
23 did not understand Swedish 
53 had recurrent cancer disease 
2 never had pelvic radiation therapy 
An introductory letter was sent to 789 
eligible survivors 
420 (88 %) control women gave informed 
consent and were sent a questionnaire 
698 (88 %) survivors gave informed consent 
and were sent a questionnaire 
81 survivors did not complete the study: 
 
52 did not return the questionnaire 
29 returned the questionnaire without 
answers 
76 controls did not complete the study: 
 
66 did not return the questionnaire 
10 returned the questionnaire without 
answers 
Reasons for non-participation: 
 
29 declined participation without 
stating any reason 
21 stated physical reasons 
17 were not reachable 
14 stated psychosocial reasons 
9 stated psychological reasons 
Reasons for non-participation: 
 
37 declined participation without 
stating any reason 
13 stated physical reasons 
5 were not reachable 
616 (78 %) survivors returned a completed 
questionnaire 
344 (72 %) controls returned a completed 
questionnaire 
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Inclusion criteria were prior pelvic EBRT, younger than 80 years of age, no 
recurrence and able to read and write Swedish. At follow-up in January 2006 
789 survivors (Stockholm n=595 and Gothenburg n=194) were eligible for the 
study. In total 497 women had died, 436 were born before 1927, 53 had had a 
recurrence, 23 were not able to read Swedish and two did in fact never 
receive any pelvic RT and were not included. Women with prior abdominal 
surgery and malignancy other than a gynecological cancer were allowed to 
participate. 
Power calculations were performed to estimate the sufficient number of 
control women. In a random sample from The Swedish Population Registry 
we received names and addresses of 366 control women, matched for 
residential area and age. An error in the matching procedure led to a younger 
control population and an additional 120 women, aged 70 to 79 were added 
to provide a better match of age of cancer survivors and control women. Eight 
out of the 486 control women were not included because they were born 
before 1927, did not understand Swedish or were previously treated with 
pelvic RT. In total 478 control women remained and were eligible for the 
study. 
 
The study population in Paper I consists of the 616 out of 789 (78 percent) 
survivors and the 344 out of 478 (72 percent) control women who participated 
in the study. 
The study population in Paper II comprised the 606 out of 616 (98 percent) 
cancer survivors and 344 (100%) control women who answered the question 
‘Have you had emptying of all stools into clothing without forewarning, the 
past six months?’ 
The study population in Paper III consists of the 519 survivors for whom it 
was possible to recover electronically stored radiation treatment dose data for 
organs at risk. 
The study population in Paper IV consists of a subset of the survivors 
described in Paper III and included the 83 survivors who were treated with 
EBRT without EBRT. 
 
Questionnaire 
The development of the questionnaire started with a qualitative preparatory 
phase lasting for 18 months. Twenty-six gynecological cancer survivors 
treated with EBRT one to ten years earlier agreed to be interviewed. The 
semi-structured interviews were tape recorded and lasted on average one 
hour each. The questions focused on the informants’ present situation, the 
current symptoms, QoL and social functioning. Verbatim transcripts were 
made by a secretary. The self-reported symptoms were sorted into areas of 
supposed anatomical origin. The symptoms and themes that were captured in 
the interviews were reformulated as questions. In addition we added 
questions based on our clinical experience, previous questionnaires from our 
research unit and through studying available literature. 
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Strålbehandling  
vid en gynekologisk cancersjukdom  
 
Face-to-face validation was performed in women within the study population 
making sure the questions were conceptually clear and correctly understood. 
The questionnaire was also validated face-to-face with non-irradiated 
persons. Participation rate, rate of missing values and logistics were tested in 
a pilot study. 
The final questionnaire consisted of ten chapters with a total of 351 questions, 
as follows: 
 
 
Demographic characteristics, obstetric data, cancer disease and cancer 
treatment: Q 1-22 
Psychological issues, QoL-measures and social functioning: Q 23-35 
Gastrointestinal symptoms and coping strategies: Q 36-150 
Urinary tract symptoms and coping strategies: Q 151-197 
Lymph edema in abdomen and legs: Q 198-217 
Pelvic bone pain: Q 218-247 
Eating habits: Q 248-256 
Sexuality and body image: Q 257-315 
Physical health, co-morbidities, medication, Body mass index (BMI), smoking 
and smoking: Q316-340 
Questions on study participation: Q 341-351 
 
 
In each part of the questionnaire we asked about the incidence, prevalence, 
intensity and duration of the symptoms when appropriate. One hundred and 
fifteen questions addressed bowel habits such as anal incontinence, leakage 
severity (soiling to all stools), forewarning or not, frequency, prevalence and 
duration as well as coping strategies and QoL conditions. 
For QoL and social functioning we used a seven-point Visual Digital scale. 
Responses ranging from 1 to 5 on the scale were defined as low to moderate 
QoL135. 
 
 
 
 
 
 
 
 
 
Figure 12. Questionnaire 
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The main data collection was carried out in January to October 2006. We sent 
an introductory letter to 789 patients and 478 controls explaining the 
objectives of the study emphasizing that their participation in the study was 
voluntary. One week later an interviewer called each informant. Those giving 
informed oral consent to participate received a postal questionnaire along 
with a letter again explaining our objectives for conducting the study. The 
cancer survivors were informed that data also were collected from their 
medical records. Three weeks later after the initial contact a thank-you card 
was sent to show appreciation for the subject’s participation or serve as a 
remainder. Yet a week later the interviewer called those who had not returned 
the questionnaire. Each questionnaire contained a number for identification to 
maintain confidentiality. Information collected from medical record included 
cancer diagnosis, treatment techniques and dose-distribution data. 
The results from the questionnaire and the data from the medical records 
were coded and transferred to the freeware data entry program Epi-Data 
(www.epidata.dk). Statistical analyses were performed using IBM SPSS 
Statistics 17.0 (IBM, Armonk, New York, United States). 
The Regional Ethics Committee has approved of the study. 
 
Contouring of organs at risk 
Ten organs at risk were identified; the anal-sphincter region, rectum, the 
sigmoid, the small intestines, the urinary bladder, the vagina, the pubic bone, 
the sacrum and finally the left and right femoral heads. Available treatment 
plans with CT slices were retrieved in the treatment planning systems and the 
organs at risk were contoured in order to calculate the dose distribution in 
these ten organs. Consistent contouring was assured by using written 
guidelines including pictures. Two persons at each clinic performed the 
contouring under the supervision of a Senior Oncologist (H.L. in Stockholm 
and A-C.W in Gothenburg) during 2006 and 2007. 
The anal-sphincter region was represented by the inner muscle layer of the 
sphincter up to the anal verge. The rectum was depicted by its outer contour 
with filling extending from the anal verge to the recto sigmoid junction. The 
sigmoid was outlined from where the rectum deviated from its mid-position to 
where it could be located in the left part of the abdomen in at least two 
consecutive slices and connecting to the colon descendens. The small 
intestines were defined as all visible small bowels in the pelvic region up to 
the caudal part of the sacroiliac joints. The urinary bladder was represented 
by its outer contour including filling (Figure 13). The pubic bone was 
contoured using the symphysis as a starting-point reaching laterally including 
the anterior parts of the superior and inferior rami. The sacrum was defined 
by the body of the sacrum, excluding the dorsal spinal processes and the 
coccyx. The left and the right femoral heads were outlined separately 
covering the head but excluding the femoral neck (Figure 14). The vagina 
was defined as an elliptical area measuring one by three cm located between 
the urethra/urinary bladder and the rectum to cervix portio or if not present to 
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the lower border of the pelvic cavity. Some of the cervical cancer patients had 
two or three silver seed markers of the cervix. 
 
 
 
 
 
 
 
 
 
 
Figure 13. Frontal view of organs at risk. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Lateral view of pelvic bones 
 
Outlining in contiguous CT slices resulted in a three-dimensional volume where 
the dose of ionizing radiation could be calculated in each volume element; i.e. 
voxel. DVHs of the ten OARs were produced for each individual patient and 
exported from the treatment planning system. The DVH was normalized to the 
total volume of each OAR (percentage of volume) except for the small 
intestines which were measured by the actual volume. The mean absorbed 
doses for EBRT for all OARs were calculated for each group of the tumor 
diagnoses. 
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Radiation therapy equipment and techniques 
Cancer treatment was administered according to local treatment programs 
and applied study protocols that were in use at the time of treatment. The 
protocols have been revised and updated gradually in accordance to new 
medical evidence. 
Three-dimensional treatment planning systems were used for the construction 
of EBRT dose plans; TMS (Nucletron, Veenendaal, the Netherlands) in 
Stockholm and Cadplan and Eclipse (Varian Medical Systems, Palo Alto, 
United States) in Gothenburg. 
The planning was based on designated CT scans performed prior to 
radiotherapy with a Siemens Somatom HiQ single slice (Siemens AG, 
München, Germany) in Stockholm and a General Electric High Speed Fx 
(Fairfield, Connecticut, United States) in Gothenburg. Scans were made in 
treatment position on a flat table top, using laser markers and conversion 
factors to electron density and with tissue heterogeneity correction applied. 
The CT slices ranged from 5 to 20 mm. The EBRT dose was prescribed 
either at isocenter or as mean dose to the target covering at least 95 percent 
of the planning target volume. Patients were treated in supine position, using 
megavoltage linear accelerators; Brown Boveri Company (now: Asea Brown 
Boveri, Zürich, Switzerland), Elekta (Elekta AB, Stockholm, Sweden), Philips 
(Koninjeklike Philips Electronics, Amsterdam, the Netherlands), Siemens and 
Varian or with a racetrack accelerator; Scanditronix (Scanditronix Medical AB, 
Uppsala, Sweden) with two opposing fields or a four-field box technique. Daily 
dose per fraction varied between 1.6 and 2.0 Gy. EBRT RT was verified by 
portal image films and with check-and-confirm systems. 
BT was applied using standardized techniques and applicator templates. The 
BT dose was prescribed according to local practice; to Point A in Stockholm 
and 2 mm outside the applicator surface in Gothenburg. In 1991-1994 the BT 
treatment in Stockholm, was administered by manually deposited intrauterine 
insertions of low dose rate 226Radium implants according to the packing 
method of Heyman136 and by intravaginal BT treatment with low dose rate 
137Cesium. A Selectron (Nucletron) remote afterloading equipment was used 
to operate the 137Cesium. Around 1994 the treatments including 226Radium 
were replaced by high dose rate 192Iridium using an afterloading device; 
Microselectron (Nucletron) in Stockholm. In Gothenburg only high dose rate 
BT treatment technique was applied by using a GammaMed 12i HDR, (Varian 
Medical System). Pre-treatment orthogonal x-ray images verified the position 
of the BT applicator. 
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5. RESULTS 
Paper I 
In all, 616 of 789 (78 percent) cancer survivors and 344 of 478 (72 percent) 
control women participated in the study. The median follow-up time was 74 
months (range 26 to 179 months). The median age for cancer survivors was 
66.0 years and for controls 57.5 years. The most common diagnose was 
endometrial cancer followed by cervical cancer as illustrated by Figure 15. 
 
 
 
 
 
 
 
Figure 15. Diagnoses in Paper I 
 
More than 90 percent of the survivors had surgery in addition to EBRT. The 
remaining 10 percent consisted of a subset of cervical and vaginal cancer 
patients who were treated without surgery. Treatment in each diagnosis is 
illustrated in Figure 16. 
 
 
Figure 16. Diagnosis and treatment 
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Nulliparity, hypertension, diabetes mellitus and heart failure were more 
prevalent in cancer survivors. Operational procedures at delivery and perineal 
injuries were more common among controls. 
 
With a median follow-up time of 6.2 years from completed EBRT, cancer 
survivors reported a higher occurrence of symptoms from all the studied organs 
compared to matched control women. 
The highes RRs for ‘Anal-sphincter region’ were ‘emptying of all stools into 
clothing without forewarning at least occasionally’ RR = 12.7 (95% CI 4.0-40.3) 
and ‘leakage of loose stools while awake at least occasionally’ RR = 6.0 (95% 
CI 3.7-9.6). 
The highest RRs for ‘Bowel’ were ‘defecation urgency at least once a week’ RR 
= 5.7 (95% CI 3.5-9.1) and ‘protracted abdominal pain lasting more than a year’ 
RR = 3.2 (95% CI 1.9-5.6). 
The highest RRs for ‘Urinary tract’ were ‘difficulties to feel the need to empty 
bladder’ RR = 2.8 (95% CI 1.5-5.4) and ‘difficulty emptying bladder at least 
occasionally’ RR = 2.7 (95% CI 1.4-5.2). 
The highest RRs for ‘Sexuality’ were ‘protracted genital pain lasting more than 
a year’ RR = 5.0 (95% CI 1.7-14.5) and ‘genital bleeding during or after 
intercourse at least once’ RR = 3.7 (95% CI 2.1-6.7). 
The highest RRs for ‘Pelvic bones’ were ‘pubic pain when walking indoors at 
least occasionally’ RR = 4.9 (95% CI 2.1-11.6) and ‘pubic pain when walking 
outdoors 500 m at least occasionally’ RR = 3.7 (95% CI 1.7-8.4). 
The highest RRs for ‘Lower abdomen and legs’ were ‘erysipelas on abdomen 
or legs’ RR = 3.6 (95% CI 1.0-12.8) and ‘lower abdomen heaviness at least 
occasionally’ RR = 2.1 (95% CI 1.5-3.0). 
All RRs were increased when survivors with surgery were excluded. 
 
 
Paper II 
In all, 606 of 616 cancer survivors (98 percent) and 344 of 344 control woman 
(100 percent) that were participating in the study had answered the question 
‘Have you had emptying of all stools into clothing without forewarning, the past 
six months?’. 
 
Seventy out of 606 (12 percent) survivors reported having the symptom 
‘emptying of all stools into clothing without forewarning’ at least occasionally 
the previous six months before answering the questionnaire. Three out of 344 
(less than one percent) of control women had had a similar experience. The 
RR between survivors and controls was 11.9 (95% CI 3.8-37.8). 
The symptom was relatively more common in cervical cancer and uterine 
sarcoma survivors as seen in Figure 17. 
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 Figure 17. Diagnoses in Paper II; all survivors and survivors with the symptom 
 
 
 
It was relatively less common with BT in survivors experiencing ‘emptying of all 
stools into clothing’ as seen in Figure 18 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 18. Treatment modalities for survivors with and without 'emptying of all stools’ 
 
Adjustment for known risk factors for fecal incontinence such as BMI >25, 
diabetes mellitus, neurological diseases, Crohn’s disease, ulcerative colitis, 
episiotomy and caesarean did not alter the result. 
 
 
 
Seventy four percent of the survivors with the symptom had a low to moderate 
QoL compared with 51 percent of survivors without the symptom. In addition 
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the survivors with the symptom were bothered by a number of other physical 
issues to a greater extent than survivors that without ‘emptying of all stools’ 
(Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Symptoms leading to bother in survivors with and without ‘emptying all stools’ 
 
 
‘Emptying of all stools kept the survivors from going to parties RR= 11.8 (95% 
CI 6.6-21.1), kept the survivors from traveling RR = 9.3 (95% CI 5.3-16.5), 
affected their work ability RR = 7.9 (95% CI, 3.8-16.4) and hindered their 
sexual life RR = 9.2; (95% CI 4.8-17.6). 
Approximately 50 percent needed to locate toilets in advance and 60 percent 
stayed close to toilet facilities at all times. Incontinence device and diapers 
were used by almost half of the affected women and thoughts and practical 
arrangements around bowel movements occupied them several hours daily. 
 
 
Paper III 
In all, we had access to electronically stored treatment plans for 519 of 616 
cancer survivors (84 percent). Proportions of diagnoses were more or less 
unchanged from the comparison with the original 616 survivors as seen in 
Figure 15 and 20. 
 
 
 
 
 
 
Figure 20. Diagnoses in Paper III; all survivors and survivors with the symptom, respectively 
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Mean absorbed dose was 46.3 Gy (±SD 8.2) in survivors with ‘emptying of all 
stools into clothing without forewarning’ compared to 43.3 Gy (±SD 5.5) in 
survivors without the symptom. Proportions of treatment modalities are 
presented in Figure 21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Treatment modalities in survivors with or without 'emptying of all stools' 
 
 
Unadjusted RRs and odds ratios (ORs) for having ‘emptying of all stools into 
clothing without forewarning’ for all organs at risk were significantly increased 
for mean doses over 50 Gy. 
Regression analysis included the risk factors ‘At least two deliveries of birth 
weight exceeding 4 kg’, ‘Anal-sphincter injury’, ‘Heart failure’, ‘Lactose and/or 
gluten intolerance’ and ‘BT dose’ in the model used for adjusting ORs for the 
mean absorbed dose levels.Adjustment led to significantly increased OR also 
for mean dose over 45 Gy to the anal-sphincter region: OR = 3.3 (95% CI 1.0-
10.5) and when excluding ‘high-dose’ BT we found OR = 4.5 (95% CI 1.2-
17.2). 
For doses over 50 Gy to the anal-sphincter region OR = 17.1 (95% CI 4.0-73.0) 
and when excluding ‘high-dose’ BT we found OR = 22.4 (95% CI 3.3-152.4), 
for the rectum OR = 4.2 (95% CI 1.0-18.2) and OR = 3.4 (95% CI 0.3-32.6), for 
the sigmoid OR = 5.6 (95% CI 1.1-26.3) and OR = 5.0 (95% CI 0.9-26.8) and 
for the small intestines OR = 3.7 (95% CI 0.8-16.4) and OR = 4.0 (95% CI 0.8-
20.2). 
 
The DVHs for survivors with and without the symptom were most widely 
separated for the sigmoid as seen in Figure 22. 
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Figure 22. Dose-volume histogram for organs at risk 
 
 
Paper IV 
This paper included 83 gynecological cancer survivors who did not receive BT 
as part of their treatment survivors for whom we had access to electronically 
stored treatment plans. By using these inclusion criteria most endometrial 
cancer survivors were excluded as seen in Figure 23. 
 
 
 
 
 
 
Figure 23. Diagnoses in Paper IV 
Survivors with ‘emptying of all stools into clothing without forewarning’ were 
slightly younger and had more often been treated for cervical cancer or 
sarcoma uteri. Proportions of treatment modalities are shown in Figure 24. 
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Figure 24. Treatment modalities in survivors with and without 'emptying of all stools' 
 
The absorbed mean dose to survivors with ‘emptying of all stools into clothing 
without forewarning’ was 52.1 Gy (±SD 11.8) compared to survivors without the 
symptom; 43.0 Gy (±SD 8.7). Among the studies organs at risk, the dose to the 
sigmoid was the best predictor of the symptom with the best AUC value and 
highest γ50-value. 
 
 
 
The response probability for developing the symptom ‘emptying of all stools 
into clothing without forewarning for 50 Gy to the sigmoid was 25 percent 
according to the RS model and 27 percent according to the Lyman model 
(Figure 25). 
 
 
 
 
 
 
 
 Figure 25. Dose response probabilities using Relative Seriality or Lyman model 
 
The volume parameters for the anal-sphincter region and the small intestines 
for the three models indicate a serial behavior of the organs for this endpoint. It 
means in practice that the maximum dose would describe the dose-effect 
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relationship for the anal-sphincter region and the small intestines best. The 
rectum and to a lesser extent the sigmoid were found to have a parallel 
behavior structure, which indicate that the mean dose would be more 
appropriate for rectum and sigmoid dose-effect relationships (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Dose-response probabilities using Relative Seriality and Lyman models for OARs 
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6. DISCUSSION 
 
Methodological considerations 
Validation is the process of assessing whether or not the scientific conclusions 
presented in a study are reliable and supported by the corresponding data. The 
validity of a study is primarily dependent on presence of bias. 
 
In order to evaluate the quality of our study data, all possible sources of bias 
must be identified and categorized step-wise. Finally the combined effect of all 
bias was used to estimate the quality of the used effect-measures. 
 
 
As guidance we have used the Hierarchical step-model137. 
 
 
PERFECT PERSON-TIME 
Step 1: Confounding 
TARGETED PERSON-TIME 
Step 2: Misrepresentation 
OBSERVED PERSON-TIME 
Step 3: Misclassification 
COLLECTED DATA 
Step 4: Analytical adjustment 
ADJUSTED EFFECT-MEASURE 
 
Figure 27. Hierarchical step-model 
 
Confounding factors138 are associated both with the exposure (absorbed 
radiation dose) and the outcome (long-term symptom) and are considered true 
causes of the outcome but are not a part of the causal chain. 
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Figure 28. Confounding 
 
If confounding factors are not considered this may lead to an over- or 
underestimation of the true association between exposure and outcome. A 
positive confounding factor will strengthen the association, whereas a negative 
confounding factor will decrease the strength of the association; ‘bias toward 
the null hypothesis’. 
 
In order to minimize systematic errors due to confounding, which may decrease 
the validity, i.e., the quality of outcome measure; we have matched control 
women and survivors by age and residence. In addition we have collected 
information on potential confounding factors through the questionnaire and 
medical records. The self-reported information included among others age, 
marital status, education, employment, residency, smoking, BMI, exercise, 
obstetric data, pelvic floor injuries, intercurrent diseases and medication. We 
also collected data on diagnosis, stage of disease, Chemotherapy, and EBRT. 
Known or suspected causal factors for the outcome were studied and adjusted 
for in the analyses. 
 
Non-participation, survivors lost to follow-up and sampling from the targeted 
person-time resulting in a partial loss of the targeted person-time may lead to 
misrepresentation. It is crucial to avoid this missing piece of information since 
the lack of knowledge results in an effect-measure that can be changed in any 
unpredictable direction. An estimation of the maximum and minimum effect of 
the non-participation can be made. 
 
Extensive measures have been carried out to minimize non-participation. The 
initial qualitative in-depth interviews captured new topics and revealed areas 
that were perceived as important and relevant for the survivors, leading to an 
increased incentive to participate. All women in Stockholm and Gothenburg 
diagnosed with a gynecological cancer disease are treated at the regional 
oncology centre at each respective University Hospital. The cohort consisted of 
unselected patients arriving consecutively to these two clinics. Control women 
matched for age and residency were recruited through random sampling from 
the Swedish Population Registry. 
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In all 1011 of the cancer survivors did not meet the eligibility criteria and were 
not included in the study-base. They were either dead, had recurrent disease, 
were too old, did not understand Swedish or had never had pelvic RT. Among 
controls 8 women were not included because of being too old, did not 
understand Swedish and had had previous pelvic RT. 
 
All the 789 eligible survivors and 478 controls were contacted on several 
occasions, by mail and by phone contributing to a high participation rate of 78 
percent for the survivors and 72 percent for the control women. The 
participation rate was assessed in the pilot study before moving on to the main 
study. The women who did not participate, either stated physical illness as the 
main reason for their decision or gave no reason at all. We lack information 
regarding health among these which results in a decrease of the quality of the 
outcome measure. 
 
Electronically stored treatment plans were reactivated for 519 of the survivors, 
in total 84 percent. Some of the tapes were broken and yet others simply 
missing. The missing data were concentrated to some of the oldest cases, but 
affected in some instances also more recent treatments. Diagnoses and doses 
among the missing dose plans were randomly distributed. 
 
Misclassification may introduce bias when the collected information is not 
true. Measuring errors that do not vary between the groups that are being 
compared, non-differential misclassification, do not typically affect the relative 
risks in case of decreased sensitivity, but in measurement with decreased 
specificity, the relative risk will approach 1.0. If misclassification is different 
between the groups, differential misclassification, the relative risk can be 
changed in any direction. 
 
To mimic the technique of “blinding”, we collected symptom information by 
means of a self-administered questionnaire answered in privacy at home 
without survivors being aware of our research hypotheses. This method 
decreased the risk of inducing interviewer-related problems due to a possible 
wish to please the care giver. The method of asking for symptom occurrence 
during the previous six months decreased the risk of recall-induced problems 
and also helped to avoid capturing temporary symptoms. The qualitative in-
depth interviews, face-to-face validation, modification of questions when 
necessary and a pilot study all aimed to construct a relevant and conceptually 
clear questionnaire. Questions for survivors and controls were identical except 
for those specifically concerning cancer disease and its treatment. The 
questionnaires were numbered to maintain confidentiality. Treatment data were 
collected from medical records to ensure correct information. Measuring errors 
due to organ movements, set-up errors and errors in the contouring of pelvic 
organs at risk may dilute the association between the dose to the organs at risk 
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and occurrence of long-term symptoms. The organs were contoured without 
previous knowledge of the survivors’ symptoms or questionnaire answers, also 
having the effect of “blinding”. 
 
Analytical considerations: Relative risks were used as an effect measure in 
many of the analyses139. Dichotomizing continuous predictors may lead to a 
loss of statistical power, but will in this case not change the obtained 
associations. A relative risk is a more intuitive and understandable way of 
illustrating the clinical effect of a certain treatment for a clinician. 
 
Findings 
Paper I 
Gynecological cancer survivors treated with pelvic RT alone or as part of 
combined treatment reported higher occurrence of late specific symptoms from 
all normal organs addressed in the study; the anal-sphincter region, the bowel, 
the urinary tract, the pelvic bones and lymph system compared to matched 
control women. In addition there was higher occurrence of symptoms related to 
sexuality among survivors. Atomized symptoms originating from the anal 
sphincter and the bowel have been less well studied and their occurrences 
among gynecological cancer survivors are not fully elucidated89, 107. The 
gastrointestinal symptom with the highest relative risk was ‘emptying of all 
stools into clothing without forewarning’ with a 12-fold increase in risk in 
survivors compared to controls. In a previous study from our group 65 prostate 
cancer survivors were assessed by a postal questionnaire and dosimetric data 
including DVHs two to four years after curative EBRT. Fecal leakage was found 
to correlate to anal-sphincter dose of 45-55 Gy. There was also a correlation 
between defecation urgency and loose stools and rectal dose of 25-42 Gy140. 
 
Late urinary side-effects appear to be less common but there are on the other 
hand few published reports on the prevalence of specific urinary symptoms 
among long-term gynecological cancer survivors. The urinary bladder has been 
regarded as less sensitive to radiation compared to the gastrointestinal 
organs115. Genitourinary complication rates following postoperative adjuvant 
EBRT in early stages of endometrial cancer have been assessed in the 
PORTEC-1 trial and the GOG99 trial. The PORTEC-1 trial reported a 
prevalence of eight percent of urinary urgency, recurrent infections and minor 
incontinence (measured by FIG glossary) compared to a prevalence of 25 
percent of unspecified urinary toxicity (measured by 1985 GOG Adverse 
Events Criteria Scale) in the GOG99 trial. Higher risks of late urinary side-
effects are reported in cervical cancer survivors, which can possibly be an 
effect of higher radiation doses 117. Most studies show that the urinary morbidity 
continues to progress decades after RT. This statement is contradicted by the 
study by Pieterse et al141, where no increase in bladder dysfunction was found 
two years after postoperative EBRT of 94 early stage cervical cancer patients. 
The short follow-up time and the fact that there were only two questions 
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concerning bladder function may have contributed to this result. In a survey of 
291 cervical cancer survivors 6.6 years after treatment Korfage et al assessed 
late symptoms and health-related QoL142. They compared self-reported 
symptoms after RT alone and postoperative EBRT. Frequent micturition was 
found in 42 percent versus 45 percent, urinary leakage in 19 percent versus 26 
percent and difficulties emptying the bladder in 6 percent versus 11 percent. 
Our results indicate that late side effects from the urinary tract following RT are 
underestimated and underreported. 
 
In a population-based cohort study of long-term early stage cervical cancer, the 
survivors reported more sexual dysfunction compared to control women143. 
This study has included all gynecological cancer disease. The impact of RT on 
sexual function has since then been confirmed in several publications142, 144-146. 
Currently there are only a few evidence based actions that deal with physical 
symptoms as reviewed by Cochrane Collaboration147 . 
 
Symptomatic bone fracture caused by osteradionecrosis is a very rare but 
disabling condition with an overall incidence less than one percent as reported 
by Feltl et al118. At a median time of 44 months (range 6-197 months) after 
pelvic EBRT with or without BT for a gynecological malignancy 0.44 percent of 
survivors had verified insufficiency fracture and pain. The main risk factor for 
developing pelvic bone pain was osteoporosis119. The condition seems to be 
underreported compared to our data, especially in survivors previously treated 
with RT only. In a previous paper from our research group we reported on 
pubic bone pain and increased frequency of pain with mean absorbed dose 
exceeding 52.5 Gy to the pubic bone148. 
Lymph edema in the lower abdomen and the legs is late symptom affecting 
gynecological cancer survivors149. In a population-based postal survey of 802 
gynecological cancer survivors 25 percent reported lymph edema or had 
symptomatic lower limb swelling. The symptoms were most pronounced in 
vulvar cancer survivors150. These results are in accordance with our result 
where survivors in general reported swollen lower abdomen and sense of 
heaviness and in 20 percent, and in addition swollen legs and sense of heavy 
legs in 35 percent. 
 
Paper II 
Seventy-four percent of the survivors with the symptom ‘emptying of all stools 
into clothing without forewarning’ reported a low to moderate QoL. This 
symptom stopped the gynecological cancer survivors from participating in 
social activities and made it difficult to have a sex life. Many of the women 
stated that they located accessible toilets before they left home. One out of 
three said that having fecal leakage had changed their personality. 
Gastrointestinal symptoms after pelvic RT have more impact on QoL than 
previously reported105 and in particular fecal leakage, which is one of the most 
stressful symptoms143. 
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Fecal incontinence occurring suddenly, unpredictably and with no time to react 
is disabling and very embarrassing. Similar results are reported in studies by 
Abayomi et al91, 151. The gynecological cancer survivors reported that chronic 
radiation enteritis with loose stools, fecal incontinence and fecal urgency had 
an impact on work, ability to perform in activities outside the house and social 
life. The lack of warning before defecation made coping strategies essential. 
Need of immediate access to a toilet has also been reported by Nout et al who 
studied 348 gynecological cancer survivors treated with either vaginal EBRT or 
EBRT for an endometrial cancer. Survivors treated with EBRT reported 
significantly higher levels of loose stools and fecal leakage and a significantly 
higher need to remain closer to a toilet which resulted in lowered social 
functioning152. In a study by Gami et al 107 cancer survivors treated with pelvic 
RT the QoL was affected in 50 percent of patients with diarrhea and in 20 
percent of patients with fecal incontinence105. 
Many cancer survivors associate current symptoms with normal ageing, not 
realizing that previously administered treatment can be the main cause. They 
may hesitate to talk about embarrassing symptoms such as fecal 
incontinence93. An important task for the health care providers is to actively ask 
for symptoms that are surrounded by taboos. 
 
Paper III 
Not many studies have reported on the relationship between anorectal dose 
parameters and the risk of late fecal incontinence in gynecological cancer 
survivors as opposed to prostate and rectal cancer survivors. In a study of 
Fiorino et al dosimetric rectal data from 506 prostate cancer patients were 
analyzed. Rectal volume receiving 40 Gy or more (V40) and surgery were the 
strongest predictors of fecal incontinence defined as ‘use of pads’153, 154. In 641 
prospectively scored (RTOG/EORTC scale) prostate cancer survivors Peeters 
et al found fecal incontinence requiring pads to be associated with anal wall 
parameters155. Similar results were reported by our own group showing a 
significant correlation between mean absorbed dose of 45 to 55 Gy to the anal 
sphincter and the risk of fecal incontinence in prostate cancer survivors156 
These result are in accordance with the present study that showed a dose-
effect relationship between mean absorbed doses over 50 Gy to the anal-
sphincter region, the rectum, the sigmoid and the small intestines. 
 
Several reports support the hypothesis that specific symptoms originate from 
specific anatomic regions. Smeenk et al reported on fecal urgency and 
incontinence origin from both the anal and rectal wall, while fecal frequency 
mostly originated from the rectal wall157. In addition they found that dose-effect 
relations differed between the described symptoms. The importance of 
discriminating between different symptoms and their origin to increase 
specificity is supported by Heemsbergen et al who found a dose-effect relation 
for fecal incontinence in the anal region and lower rectum158. The sigmoid colon 
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has been suggested by Fonteyn et al as being co-responsible for the 
development of lower intestinal toxicity besides the anal sphincter and the 
rectum159. In addition was the small bowel volume receiving 50 to 60 Gy 
predictive for the development of late side effects, which is in line with our 
results. 
 
The dose contribution from BT is difficult to estimate because of the use of 
different techniques regarding isotopes, applicators, anatomical arrangements 
and doses in the absence of three-dimensional treatment planning. We have 
made the assumption that 192Iridium BT used postoperatively in endometrial 
cancer patients with a prescribed total dose of at most 11.25 Gy did not 
substantially affect the studied OARs. In an effort to investigate the effect of 
‘high’ doses of BT we excluded survivors that were treated with 192Iridium 
exceeding 11.25 Gy or 226Radium with or without 137Cesium. The resulting 
prevalence ratios were even higher which indicate that EBRT to the four OARs 
is related to ‘emptying of all stools into clothing without forewarning’. 
Normal-tissue injury induced by ionizing radiation is thought to be a progressive 
process. Still, there are reports showing both increase and decrease of rectal 
symptoms with time in prostate cancer survivors160. In the present study there 
was a tendency towards an increase of symptom occurrence with time, but it 
was not statistically significant during follow-up from 28 to 120 months after 
completing pelvic radiation therapy. 
 
Paper IV 
 
Among the four studied organs at risk, the dose to the sigmoid was found to be 
the best predictor of the symptom ‘emptying of all stools without forewarning’, 
having the best Area Under the Curve-value (AUC-value) and the highest 
normalized dose response gradient (γ50-value). It is still import to mention the 
fact that the figures do not differ very much. The response probability for 50 Gy 
was 25 percent according to the relative seriality and 27 percent according to 
the Lyman model, which indicates that either model can be used. The volume 
parameters obtained for the anal-sphincter region and the small intestines 
indicate a serial behavior of the organs for this endpoint. The rectum and to a 
lesser extent the sigmoid were found to have a parallel structure. The values 
from the maximum likelihood estimates of the used models and the Log 
Likelihood (LL) values showed no significant difference between the Relative 
Seriality and the Lyman models, and either method could be used in order to 
predict the probability of the symptom and dose to the OARs. 
Although the sigmoid is highly mobile and the exact location is difficult to 
estimate, the dose distribution in its anterior wall appears almost uniform as 
reported by Waldenström et al161 and thus the exact location at contouring may 
become less critical. 
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Fonteyn et al reported late radiation therapy induced lower intestinal toxicity 
following IMRT in 241 prostate cancer patients159. The late side-effects 
included five symptoms from the RTOG toxicity score supplemented with 
urgency, fecal incontinence and anal pain. Grade 2 symptoms were found in 13 
percent of the survivors. There was a correlation between sigmoid volume 
parameters and grade 1-2 symptoms suggesting that the sigmoid should be 
considered as an organ at risk, which is in accordance with our results. 
 
Studies concerning gynecological cancer survivors and dose-volume response 
parameters for the anal sphincter and bowel for fecal incontinence symptoms 
are scarce. In a radiobiological study of 65 prostate cancer survivors assessed 
with a study-specific questionnaire and access to three-dimensional dose 
distributions, Mavroidis et al162 found a parallel behavior of the anal sphincter 
with fecal incontinence as end point. These results were confirmed in a study 
by Peeters et al163 including 468 prostate cancer survivors evaluated after RT. 
 
A statistically significant correlation was found between radiation to the anal-
sphincter region and the risk of fecal leakage in the interval of 45 to55 Gy in a 
study including 72 prostate cancer survivors assessed with a questionnaire two 
to four year after RT by al-Abany et al140. 
 
Other factors have been found to influence the development of ‘emptying of all 
stools without forewarning’. Alsadius et al reported that current smokers among 
prostate cancer survivors had an increased risk of having the symptoms with a 
prevalence ratio of 4.7 (95% CI 2.3-9.7)164. Corresponding data for the 
gynecological cancer survivors did not show any significant difference among 
survivors with or without the symptom who were current smokers. The only 
factor that was significantly associated with having this specific fecal 
incontinence was heart failure. 
 
The mean absorbed to anal-sphincter region and bowel organs is related to the 
late fecal incontinence symptom ‘emptying of all stools into clothing without 
forewarning’. Besides the anal-sphincter region and the rectum also the 
sigmoid and small intestines should be contoured and saved separately in RT. 
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7. GENERAL CONCLUSIONS 
 
Gynecological cancer survivors having undergone pelvic radiation therapy 
alone or as part of combined treatment between 1991 and 2003 report a higher 
occurrence of symptoms from the gastrointestinal and urinary tract as well as 
lymph edema, sexual dysfunction and pelvic pain compared with non-irradiated 
control women. 
 
 
Twelve percent of women with a history of gynecological cancer treated with 
pelvic radiation therapy reported ‘emptying of all stools without forewarning’ 
and 74 percent of them reported low to moderate quality of life. This symptom 
kept the cancer survivors from social activities and hindered their sexual lives. 
A majority of these women located accessible toilets in advance and spent 
several hours every day on practical arrangements around defecation. 
 
 
Mean absorbed external doses to the anal-sphincter region, the rectum, the 
sigmoid and the small intestines are related to the risk of ‘emptying of all stools 
into clothing without forewarning’ in long-term gynecological cancer survivors. 
 
 
Radiobiological modeling indicates that the dose to the sigmoid is the best 
predictor of the occurrence of ‘emptying of all stools into clothing without 
forewarning’. The volume parameters indicate that the anal sphincter and small 
intestines behave serially while the rectum behaves parallel. The sigmoid has a 
mixed serial and parallel behavior. Other factors in addition to external beam 
radiation therapy dose and heart failure may be related with the development of 
the symptom. 
 
 
The implications of our study are that; 
 
Health-care providers need to actively ask patients about specific symptoms in 
order to provide proper diagnostic investigations and management. 
 
 
Not only the rectum and anal sphincter should be contoured and spared 
separately in radiation therapy planning but also the sigmoid and the small 
intestines. 
 
 
Dose-restriction to the involved organs at risk may in the future prevent 
‘emptying of all stools into clothing without forewarning’, a severe socially 
disabling symptom which today affects one out of ten gynecological cancer 
survivors. 
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8. SWEDISH SUMMARY/SVENSK SAMMANFATTNING 
Gynekologisk cancer och strålbehandlingsrelaterade symtom 
I Sverige insjuknar årligen cirka 2 900 kvinnor i en gynekologisk 
cancersjukdom. Livmoderkroppscancer, den vanligaste cancersjukdomen, 
drabbar cirka 1 400 kvinnor, cancer i äggstockar och äggledare knappt 800, 
livmoderhalscancer drygt 400, cancer i de yttre könsdelarna 127 kvinnor och 
de mer sällsynta livmodersarkomen och slidcancer drabbar tillsammans drygt 
100 kvinnor årligen. Antalet kvinnor som överlevt en gynekologisk 
cancersjukdom blir allt fler och många av dessa kvinnor har erhållit 
strålbehandling mot bäckenområdet som enda behandling, eller som del av 
behandling i kombination med operation och eller kemoterapi. 
Strålbehandling riktas mot det sjuka området men drabbar även 
omkringliggande normal vävnad, så kallade riskorgan vilket är bakgrunden till 
att biverkningar kan uppkomma. Hur stor stråldos och volym som olika 
riskorgan kan erhålla innan kvinnan drabbas av livskvalitetsnedsättande 
symtom är ofullständigt klarlagt. Kunskap om dessa faktorer kan bidra till en 
förbättrad strålbehandling i framtiden och möjliggöra att canceröverlevare kan 
besparas från symtom som inverkar på deras livskvalitet. 
Det övergripande målet med denna avhandling var att kartlägga förekomsten 
av sent uppträdande symtom från bestrålade riskorgan i bäckenområdet 
bland gynekologiska canceröverlevare. Vi ville också studera hur dos av 
joniserande strålning och volym av bestrålade bäckenorgan bidrar till 
utvecklandet av ett specifikt livskvalitetsnedsättande symtom. Detta är 
kunskap vill vi använda till att förbättra vården för dagens och morgondagens 
gynekologiska cancerpatienter. 
I denna epidemiologiska studie deltog 789 gynekologiska canceröverlevare 
från Stockholm och Göteborg som genomgått strålbehandling mot 
bäckenområdet, som enda behandling eller som del av 
kombinationsbehandling, under åren 1991-2003. Som kontrollgrupp 
tillfrågades 478 slumpvis utvalda kvinnor, matchade för ålder och bostadsort, 
från befolkningsregistret. 
En 18 månader lång förberedande kvalitativ fas utgjorde grunden för studien. 
Vi inledde med att intervjua 26 kvinnor som tidigare fått yttre strålbehandling 
mot bäckenområdet i botande syfte för gynekologisk cancer. I ett icke 
tidsbegränsat samtal, oftast timslångt, berättade kvinnorna om de symtom 
och besvär de hade, många utan att själva relatera detta till genomgången 
behandling. Samtalet spelades in och skrevs därefter ut ordagrant av en 
sekreterare. Materialet sorterades och delades in efter teman. 
Dessa intervjuer varvade med litteraturstudier och våra samlade kliniska 
erfarenheter av gynekologisk cancer och strålbehandling låg till grund för vårt 
fortsatta arbete med att utveckla ett studiespecifikt frågeformulär. När 
frågeformuläret började närma sig en slutgiltig version testade vi frågor och 
svarsalternativ i en ansiktsvalidering med 20 personer. Testpersonerna 
uppmanades att resonera högt kring frågornas begriplighet och om 
svarsalternativen var klara och rimliga. Detta genererade ett antal 
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förändringar, varefter formuläret åter testades tills dess alla deltagare uppgav 
att de förstod alla frågor och svarsalternativ. Det slutgiltiga frågeformuläret 
bestod av 351 frågor och omfattade frågor om symtom från tarm, urinvägar, 
skelettsmärtor, lymfsvullnad och sexualitet. Frågor om livskvalitet, kost, andra 
sjukdomar och sociodemografiska frågor ingick också. 
Därefter genomförde vi en förstudie med 20 kvinnor ur studiepopulationen för 
att undersöka logistiken kring utskick och svar samt om svarsfrekvensen var 
acceptabel. Arton av 20 kvinnor besvarade formuläret och en svarsfrekvens 
överstigande 80 procent gav oss klarsignal att gå vidare med huvudstudien. 
Huvudstudien, den kvantitativa fasen, startade genom att vi skickade ut en 
inbjudan till de 789 gynekologiska canceröverlevare som uppfyllde våra 
inklusionskriterier för deltagande i studien; födda 1927 eller senare, kunna 
läsa och skriva svenska, och inte ha haft återfall i sin cancersjukdom. Samma 
förfrågan skickades till de 478 kvinnor som slumpmässigt tagits fram ur det 
svenska befolkningsregistret och som utgjorde jämförelsegruppen. 
Exklusionskriterier för kontrollgruppen var; om de hade haft en gynekologisk 
cancersjukdom eller fått strålbehandling mot bäckenområdet. De skulle också 
var födda 1927 eller senare och ambitionen var att få en likartad fördelning av 
ålder och bostadsort. 
Alla dessa kvinnor, över 1 000 stycken, blev uppringda och tillfrågade om de 
ville delta. De som gav sitt informerade samtycke fick ett frågeformulär per 
post. Ett par veckor efter det att formuläret skickats ut, skickade vi ett tackkort 
som samtidigt fungerade som en påminnelse för dem som ännu inte skickat 
tillbaka formuläret. De som därefter fortfarande inte skickat tillbaka formuläret 
blev uppringda på nytt och sammanlagt genomfördes över 2 000 
telefonsamtal. Efter sju månaders datainsamling hade 616 (78 procent) 
canceröverlevare och 344 (72 procent) kontroller skickat tillbaka ett ifyllt 
formulär. Data från formulären matades in i en databas varefter informationen 
kunde bearbetas statistiskt. Information om behandlingstekniker inhämtades 
från den medicinska journalen. 
Vi kunde lokalisera och återaktivera tidigare strålplaner från 519 (84 procent) 
canceröverlevare. Genom att markera varje riskorgans anatomiska gränser 
på de skiktröntgenbilder som togs inför behandlingen, kunde vi mäta 
bäckenorganens volym och stråldos. Med hjälp av en skriftlig manual som vi 
gemensamt kommit överens om och i samarbete med röntgenläkare, ritade vi 
på ett enhetligt sätt ut konturerna av tio riskorgan; ändtarmens slutmuskel, 
ändtarmen, den S-formade delen av tjocktarmen (sigmoideum), den del av 
tunntarmen som var belägen i lilla bäckenet, slidan, urinblåsan, korsbenet, 
blygdbenet samt höger och vänster höftkula. Arbetet med inritningarna var 
omfattande och tog mer än ett år att slutföra. 
Våra resultat visade en medianuppföljningstid på 74 månader (spridning 26 till 
179 månader) efter avslutad strålbehandling. Den vanligaste diagnosen var 
livmoderkroppscancer (59 procent) följt av livmoderhalscancer (23 procent). 
Majoriteten (90 procent) av canceröverlevarna hade förutom yttre 
strålbehandling även genomgått operation. De gynekologiska 
canceröverlevarna rapporterade en högre förekomst av symtom från alla de 
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normala vävnader som studerats (d v s symtom från ändtarmens slutmuskel, 
tarmkanalen, urinvägar, bäcken skelettet, nedre delen av buken och ben samt 
sexuellt relaterade symtom) jämfört med kvinnor från normalbefolkningen. 
Hälften av canceröverlevarna i studien läckte avföring i samband med 
avföringsträngningar, jämfört med 12 procent av kvinnorna i 
jämförelsegruppen. Den högsta relativa risken, 12.7, fann vi för symtomet 
’ofrivillig total tarmtömning i kläderna utan förvarning’, vilket drabbade 70 av 
616 (12 procent) canceröverlevare jämfört med 1 kvinna i kontrollgruppen 
(0.9 procent). Av de canceröverlevare som rapporterade ’ofrivillig total 
tarmtömning i kläderna utan förvarning’ hade 74 procent nedsatt livskvalitet. 
Detta symtom hindrade de drabbade kvinnorna att delta i sociala aktiviteter 
och inverkade på deras sexualliv. 
En medelstråldos överstigande 50 Gy till ändtarmens slutmuskel, ändtarmen, 
sigmoideum och tunntarmen var associerad med symtomet ’ofrivillig total 
tarmtömning i kläderna utan förvarning’. Om man dessutom tog hänsyn till 
riskfaktorer för avföringsläckage så var en medelstråldos överstigande 45 Gy 
till ändtarmens slutmuskel associerad med symtomet. Matematiska 
beräkningar talar för att dosen till sigmoideum bäst kan förutsäga risken att 
drabbas av ’ofrivillig total tarmtömning i kläderna utan förvarning’. 
Sammanfattningsvis har gynekologiska canceröverlevare en ökad risk att få 
’ofrivillig total tarmtömning i kläderna utan förvarning’ efter strålbehandling 
mot bäckenområdet. Detta symtom som inverkar på sexualitet och hindrar 
sociala aktiviteter är relaterat till medel dosen av yttre strålbehandling till 
tarmkanalen och ändtarmens slutmuskel. Dosen till sigmoideum kan bäst 
förutsäga denna risk. Genom att begränsa stråldosen till dessa riskorgan kan 
detta gravt handikappande symtom förebyggas i framtiden. 
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